As seen from Figure S1, although the relative mRNA levels of MHC-I molecules in immunotherapy responders’ tumors are variable compared with non-responders’ tumors depending on the cancer types, the gene expression levels of HLA-A, HLA-B, HLA-C and B2M are relatively higher in responders’ tumors than of non-responders’ tumors across most cancers, including CRC. This evidence concerns the gene HLA-A and colorectal carcinoma.